
    
      As specified by the protocol, primary and secondary efficacy analyses will be evaluated in
      gastric cancer participants with PD-L1 CPS ≥1 (all participants) and PD-L1 CPS ≥10 (OS) by
      comparing the pembro mono arm or pembro combo arm separately to the SOC arm.
    
  